Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
Horm Mol Biol Clin Investig ; 42(1): 87-98, 2021 Feb 04.
Article in English | MEDLINE | ID: covidwho-1067448

ABSTRACT

The COVID-19 pandemic has not only led to a worldwide socio-economic depression, but has also had the highest health impact on the geriatric population. Elderly population, due to various reasons such as low immunity, pre-existing co-morbidities such as hypertension, cardiovascular diseases or diabetes, are obviously predisposed to develop severe infections and exhibit a high mortality rate. This is because of many reasons which include the atypical presentation in the geriatric population which might have led to diagnostic delay. As per the WHO guidelines to perform RT-PCR only on the symptomatic individuals, a very small portion of individuals were tested, leaving a fraction of population undiagnosed. Therefore, there remained a chance that many asymptomatic individuals such caregivers, healthcare professionals, family members were undiagnosed and might have carried this virus to the geriatric patients. Also, many countries were not prepared to handle the burden on their healthcare system which included sudden increased demand of ICU beds, mechanical ventilation etc. As a result, they had to make decision on who to be admitted. Atypical presentation in geriatric population may include afebrile or low-grade fever, absence of cough, malaise, muscle pains, dyspnoea etc. Geriatric population shows a more severe type of pneumonia, significantly higher number of neutrophils and C-reactive protein, less lymphocytes and a higher proportion of multiple lobe involvement. Extreme social suppression during COVID-19 pandemic has increased the risk of mental and physical adverse effects that has made older adults more vulnerable to depression and anxiety.


Subject(s)
Aging/physiology , COVID-19/epidemiology , COVID-19/pathology , Age Factors , Aged , Aged, 80 and over , Aging/immunology , COVID-19/diagnosis , COVID-19/immunology , Delayed Diagnosis , Geriatrics , Humans , Middle Aged , Pandemics , Prognosis , SARS-CoV-2/immunology , Severity of Illness Index
2.
Horm Mol Biol Clin Investig ; 42(1): 99-104, 2021 Feb 04.
Article in English | MEDLINE | ID: covidwho-1067447

ABSTRACT

The uncontrolled spread of the COVID-19 pandemic which originated in China created a global turmoil. While the world is still busy figuring out a cure for the deadly disease, scientists worked out on many theories and conducted several studies to establish a relationship between the infection and other known diseases. Cardiovascular diseases (CVD) are one of the major complications of this infection after the respiratory manifestations. Individuals with cardiovascular complication are said to be more susceptible to acquiring the infection because the novel coronavirus uses the ACE2 receptor for its entry inside the cell and there is a high level of ACE2 expression in individuals with cardiovascular complications because of the enzyme's anti-hypertrophic, anti-fibrotic and anti-hypertensive effects on the heart. Individuals who belong to the older age group are also more susceptible. Knowing the above information, it might seem that using ACE2 inhibitors would help to slow or prevent the entry of the novel coronavirus but it would also at the same time prove to have deleterious effects on the cardiovascular system as the protective functions of ACE2 would be lost. While the search for a cure still continues it has been stated many a times that the conditions might worsen with time and the only way to keep ourselves and our family safe would be to follow the appropriate social distancing methods and get a COVID test if we experience any of the major symptoms.


Subject(s)
COVID-19/epidemiology , Cardiovascular Diseases/epidemiology , Age Factors , Aged , Aged, 80 and over , Angiotensin-Converting Enzyme 2/antagonists & inhibitors , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , COVID-19/complications , COVID-19/pathology , COVID-19/therapy , Cardiovascular Diseases/complications , Cardiovascular Diseases/therapy , Comorbidity , Disease Susceptibility/epidemiology , Humans , Middle Aged , Pandemics , Risk Factors , SARS-CoV-2/drug effects , SARS-CoV-2/physiology , Virus Internalization/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL